On October 5, 2022 Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, reported that an abstract highlighting further in vivo and in vitro preclinical data for AB-101, the Company’s clinical-stage ADCC-enhancer product candidate, was accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022 (Press release, Artiva Biotherapeutics, OCT 5, 2022, View Source [SID1234621710]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation are as follows:
The abstract will be available for viewing on November 7 at 8:00 am EST at the Journal for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (JITC) website (JITC link to be provided on the SITC (Free SITC Whitepaper) Annual Meeting website at View Source). The poster will also be available for viewing on November 10 at 9:00 am EST at View Source.
The poster will present data on the universal use of an ADCC-enhancer NK cell, AB-101, in combination with ADCC-mechanistic therapeutic antibodies and will describe a broader set of antibody combinations beyond rituximab. Artiva is conducting a Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT04673617) to assess the safety and clinical activity of AB-101 alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (NHL) who have progressed beyond two or more prior lines of therapy.